Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grand SLAM: Short versus Long Adjuvant Immunotherapy After Radical Surgery for High-Risk Cutaneous Melanoma
2023-509994-22-00Phase 3Authorised
- Sponsor
- Uppsala University Hospital, North Estonia Medical Centre Foundation, Rigas Austrumu kliniska universitates slimnica SIA, Universita Degli Studi Di Perugia, Vilniaus universiteto ligonine Santaros klinikos VšĮ
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nivolumab and pembrolizumab in melanoma (2 arms), sponsored by Uppsala University Hospital, North Estonia Medical Centre Foundation, Rigas Austrumu kliniska universitates slimnica SIA, Universita Degli Studi Di Perugia, Vilniaus universiteto ligonine Santaros klinikos VšĮ. Primary endpoints: Distant metastatic free survival and Relapse-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-509994-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509994-22-00.